ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer

April 2, 2014

Cambridge, MA — (BUSINESS WIRE)—April 2, 2014 – ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer.  Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning.  He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D.

Mr. Cole is a seasoned pharmaceutical executive with more than 25 years of industry experience and a deep background in rare and orphan pharmaceutical markets. Prior to joining ARIAD, he spent seven years at Shire Pharmaceuticals, most recently as senior vice president, strategic planning and program management and as a global franchise head, and before that, as vice president, business development.  Previously, he held senior positions in business and corporate development at Oscient Pharmaceuticals (formerly Genome Therapeutics) and at Millennium Pharmaceuticals and its affiliates.  Mr. Cole led numerous successful acquisitions both at Shire and Oscient.  

“Hugh is a thoughtful and experienced executive who brings great value to our leadership team,” stated Dr. Berger. “He will be integral in seeking business and corporate development opportunities for ARIAD, including a commercial partnership for Iclusig® in Japan, as well as helping to further maximize our oncology pipeline.” 

Hugh started his career as an investment analyst at Fred Alger Management and then as a Principal at the Wilkerson Group, a consulting and advisory firm.  He has an AB degree in chemistry from Harvard and an MBA degree from the Wharton School at the University of Pennsylvania, focused on healthcare management and finance.  


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines.  ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.  ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.  For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.